首页 / 院系成果 / 成果详情页

Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study  期刊论文  

  • 编号:
    150E6C1EAA94E736238986173158207E
  • 作者:
    Ning, Tao(宁涛)#[1]Li, Danyang#[1]Deng, Ting[1];Bai, Yuxian[2];Chen, Ye[3];Wang, Zhiyu[4];Hu, Bin[5];Ba, Yi(巴一)*[1,6]Lu, Wei(陆伟)*[7]
  • 语种:
    英文
  • 期刊:
    CANCER ISSN:0008-543X 2024 年 130 卷 18 期 (3137 - 3146) ; SEP 15
  • 收录:
  • 关键词:
  • 摘要:

    BackgroundEffective systemic therapy remains limited for advanced esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC), particularly after prior failed treatment with immune checkpoint inhibitors (ICIs). Theoretically, a combination of tyrosine kinase inhibitors (TKIs) with ICIs may restore immunotherapy sensitivity.MethodsIn this phase 1b study, patients received AL2846, an antiangiogenic TKI with multiple targets (c-MET, VEGFR1, c-KIT, Axl, RET, KDR, and VEGFR3), in combination with an anti-PD-L1 antibody (TQB2450) until disease progression, intolerable toxicity, death, or discontinuation for any cause. The primary end points included overall response rate (ORR) and safety, with secondary end points encompassing progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response.ResultsBetween November 2021 and September 2022, 18 patients with ESCC and 15 patients with HCC, whose ORR was 11.1% (95% confidence interval [CI], 3.1%-32.8%) and 0%, respectively, were enrolled. Adverse events (AEs) of any grade and treatment-related AEs were documented in 32 patients (97.0%) and 31 patients (93.9%), respectively. Grade 3 or higher AEs were observed in 10 patients (30.3%), with vomiting (6.1%) and infectious pneumonia (9.1%) being the most prevalent. Median PFS and OS values were 3.22 months (95% CI, 1.35-5.68 months) and 5.98 months (95% CI, 3.71-8.87 months), respectively, in patients with ESCC, and 5.55 months (95% CI, 2.66 months to not evaluable [NE]) and 16.72 months (95% CI, 4.86 months to NE), respectively, in patients with HCC. The DCRs were 66.7% (95% CI, 43.75%-83.72%) in patients with ESCC and 73.3% (95% CI, 48.05%-89.10%) in patients with HCC.ConclusionsCombined TQB2450 and AL2846 therapy exhibited a favorable safety profile in immunotherapy-refractory patients with advanced ESCC and HCC. This single-arm, multicenter, open-label, phase 1b cohort trial aimed to estimate the safety and efficacy of anti-PD-L1 antibody TQB2450 and tyrosine kinase receptor inhibitor AL2846 combination therapy in patients with immunotherapy-refractory advanced esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC). The combination therapy exhibited a favorable safety profile in immunotherapy-refractory patients with advanced ESCC and HCC.

  • 推荐引用方式
    GB/T 7714:
    Ning Tao,Li Danyang,Deng Ting, et al. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study [J].CANCER,2024,130(18):3137-3146.
  • APA:
    Ning Tao,Li Danyang,Deng Ting,Bai Yuxian,&Lu Wei.(2024).Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study .CANCER,130(18):3137-3146.
  • MLA:
    Ning Tao, et al. "Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study" .CANCER 130,18(2024):3137-3146.
  • 入库时间:
    9/8/2024 12:00:30 PM
  • 更新时间:
    9/8/2024 12:00:30 PM
  • 条目包含文件:
    文件类型:PDF,文件大小:
    正在加载全文
浏览次数:48 下载次数:0
浏览次数:48
下载次数:0
打印次数:0
浏览器支持: Google Chrome   火狐   360浏览器极速模式(8.0+极速模式) 
返回顶部